Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan

Summary

A multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several European countries.

Conditions

• NASH - Nonalcoholic Steatohepatitis
• NAFLD
• Metabolic Syndrome

Interventions

DIAGNOSTIC_TEST

LiverMultiScan

LiverMultiScan is an imaging technique which is able to identify early liver disease.

Sponsors & Collaborators

• University of Coimbra

  collaborator OTHER

• University Hospital Ulm

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• Liverpool University Hospitals NHS Foundation Trust

  collaborator OTHER_GOV

• University Hospital Southampton NHS Foundation Trust

  collaborator OTHER

• King's College Hospital NHS Trust

  collaborator OTHER

• NHS Greater Glasgow and Clyde

  collaborator OTHER

• Glasgow Royal Infirmary

  collaborator OTHER

• Ninewells Hospital

  collaborator OTHER

• Royal Infirmary of Edinburgh

  collaborator OTHER

• St George's University Hospitals NHS Foundation Trust

  collaborator OTHER

• Perspectum

  lead INDUSTRY

Principal Investigators

• Matthias Dollinger, MD · University Hospital Ulm

• Dimitar Tonev, MD · Perspectum Diagnostics

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-09-05

Primary Completion

2020-12-31

Completion

2020-12-31

Countries

• Germany
• Netherlands
• Portugal
• United Kingdom

Study Locations